IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
NCT02028039
·
clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
OTHER
Sponsor class
Conditions
Leukemia
Interventions
DRUG:
IPI-145
BEHAVIORAL:
Follow-up Visit/Call
Sponsor
M.D. Anderson Cancer Center
Collaborators
[object Object]